The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S
Why Should I Participate in a GERD Clinical Trial?
See List of Current Clinical Studies with GIA: https://gialliance.com/research/ Commonly referred to as acid reflux or heartburn, gastroesophageal reflux disease (GERD) affects roughly 20% of adults in the United States. It is usually a manageable disease, but if overlooked,... Read More